Dengue Hemorrhagic Fever
37
0
1
35
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
25 trials with published results (68%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
2.7%
1 terminated out of 37 trials
97.2%
+10.7% vs benchmark
27%
10 trials in Phase 3/4
71%
25 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (37)
Evaluating Public Awareness and Preventive Actions for Dengue Fever in Sudan Amidst Ongoing Crises
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients
Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
Efficacy and Safety of Dengue Vaccine in Healthy Children
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age